Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

PALO ALTO, Calif., Sept. 5, 2017 -- (Healthcare Sales & Marketing Network) -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and D... Biopharmaceuticals, FDA Eiger BioPharmaceuticals, Pegylated Interferon Lambda, Hepatitis Delta Virus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news